R
estorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the surgical procedure of choice in patients with medically refractory ulcerative colitis (UC), UC with colonic dysplasia, and familial adenomatous polyposis. [1] [2] [3] [4] This procedure allows for removal of the affected colon and rectum, improvement of symptoms, avoidance of medications in UC, substantial reduction in the risk of colorectal cancer, and the preservation of gastrointestinal continuity. [5] [6] [7] Although most experience good functional outcomes following IPAA, several complications may occur in the immediate postoperative period and long-term. 6, 8 Of the long-term complications, pouchitis is most common. 7, 8 Up to 50% of patients with UC develop at least 1 episode of pouchitis following IPAA. 5, 9 Meanwhile, pouchitis in familial adenomatous polyposis has been thought to be relatively uncommon, with a reported incidence of 0% to 11%. 8, 10, 11 More recent studies, however, suggest that pouchitis is a more frequent complication in familial adenomatous polyposis than previously recognized, occurring in 19% to 22% of patients. 12, 13 Pouchitis is an idiopathic inflammatory condition of the ileal pouch. Although the exact cause of pouchitis remains unclear, it is thought to result from an abnormal mucosal immune response to alterations among mucosal and luminal microflora in genetically susceptible patients. [14] [15] [16] It represents a spectrum of disease, ranging from acute, antibiotic-responsive to chronic, antibiotic-resistant pouchitis. 7, 15 Pouch microbiota is believed to play an important role in the pathogenesis of pouchitis, as suggested by the observation that pouchitis occurs only after restoration of the fecal stream through the pouch. 16 Furthermore, antibiotics are the most effective treatment of pouchitis, whereas probiotics have shown efficacy in the prevention and remission of pouchitis. 17 Fecal stasis has been identified as a possible risk factor for the development of pouchitis, potentially caused by the alteration of commensal intestinal bacteria. 15, 18 Following IPAA, fecal stasis is driven by mechanisms that impair pouch emptying, including mechanical obstructions (ie, anastomotic strictures) and evacuation disorders, such as nonrelaxing pelvic floor dysfunction (N-RPFD). N-RPFD, or dyssynergic defecation, is defined by the paradoxical contraction and/or impaired relaxation of pelvic floor and anal muscles during defecation. [19] [20] [21] Importantly, biofeedback therapy has been shown to be effective in patients with N-RPFD and an intact colon. [22] [23] [24] However, biofeedback for N-RPFD in patients with IPAA has not been well studied. We herein aim to determine in patients with IPAA and symptoms suggestive of a pouch evacuation disorder (1) the overall frequency of N-RPFD, (2) the frequency of N-RPFD in patients with chronic pouchitis (CP) compared with those with a healthy pouch, and (3) the effectiveness of pelvic floor retraining in patients with an IPAA and N-RPFD.
Methods
The institutional review board at Mayo Clinic in Rochester, Minnesota approved a retrospective cohort study of all patients with previous IPAA who underwent anorectal manometry (ARM) between January 1, 2000, and March 1, 2015, using the Mayo Clinic electronic medical record (institutional review board #15-005675). Patients were identified for the study using Current Procedural Terminology codes for IPAA (44152, 44153, 44158, 44211, and 45113) and ARM (91120 and 91122). Included was any patient 16 years old who consented to research and underwent IPAA with subsequent ARM with or without balloon expulsion testing (BET) at Mayo Clinic in Rochester, Minnesota (Figure 1 ). Patients were excluded from the study if ARM was performed outside of Mayo Clinic or if the patient was diagnosed with Crohn's disease of the pouch. Medical records of all patients meeting criteria were reviewed and data abstracted for relevant demographics, clinical features, and outcomes. Study data were collected and managed using REDCap software licensed by the Mayo Clinic.
The primary endpoint was the diagnosis of N-RPFD in any patient with IPAA with or without CP who presented with symptoms suggestive of a pouch evacuation disorder (ie, abdominal and/or pelvic pain, bloating, constipation, straining, or incomplete evacuation) for which ARM was performed. Diagnostic criteria for N-RPFD included 1 or more of the following: (1) abnormal BET (>200 g added in the left lateral position or >60 seconds before balloon expulsion in the seated position); (2) a total of 2 abnormal ARM values of elevated mean resting anal pressure, reduced pouch-anal gradient, reduced rectal (pouch) pressure, anal relaxation <20%, or an elevated residual anal pressure; (3) barium or magnetic resonance defecography showing >50% retained contrast; or (4) external anal sphincter electromyography (EMG) demonstrating elevated baseline activity with paradoxical increase or failure to appropriately relax during simulated defecation.
Pouchitis was diagnosed based on clinical presentation with typical pouchitis symptoms (increased frequency and looser consistency of bowel movements compared with baseline, abdominal and/or pelvic cramping, rectal bleeding, urgency, and/or fecal incontinence) and evidence of endoscopic inflammation (mucosal edema, granularity, friability, erythema, exudate, erosions, ulcerations, and/or loss of vascular pattern) during at least 1 symptomatic episode. 12 CP was defined as >3 pouchitis episodes per year, active pouchitis symptoms lasting >4 weeks despite antibiotic therapy, or the requirement of chronic antibiotic or anti-inflammatory therapy to control pouchitis symptoms. Our secondary endpoint was symptomatic improvement of those who completed biofeedback therapy at Mayo Clinic in Rochester, Minnesota after being diagnosed with N-RPFD. The pelvic floor retraining program at our institution consisted of a standardized 2-week course conducted Monday through Friday for a total of 10 days of individualized sessions. Each patient worked with a single, certified biofeedback therapist throughout the duration of the course. Home units were not routinely used. During the first week, each patient met with their therapist for 30-to-60-minute sessions 3 times daily, which was reduced to 2 sessions per day during the second week. Each patient met with their referring gastroenterologist or colorectal surgeon during the last week of the course to assess response to biofeedback therapy. The degree of clinical response was determined via chart review based on the referring physician's subjective global assessment and/or the Global Rating of Change scale at this initial visit following completion of biofeedback therapy. The Global Rating of Change scale is a patient-rated scale used to determine the degree of symptomatic response to a specific therapy ranging from -7 ("a very great deal worse") to þ7 ("a very great deal better"), with 0 representing no change in symptoms.
The frequency of N-RPFD in all patients was determined. The frequency of N-RPFD was then compared between those with and without CP. Univariate statistical analysis of the frequency of specific patient demographics and clinical characteristics in those with and without CP was performed using chi-square and Kruskal-Wallis 1-way analysis of variance. P < .05 was used for statistical significance. Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc, Cary, NC).
Results
In total, 1233 patients underwent IPAA during the timeframe specified for this study. One hundred thirtyeight patients were identified as having undergone IPAA with ARM performed at Mayo Clinic in Rochester, Minnesota. Of these, 2 were excluded because of ARM being performed and interpreted outside of Mayo Clinic and 25 were excluded for subsequent diagnosis of Crohn's disease of the pouch. Of the 111 patients who met inclusion criteria, 66 (59.5%) were diagnosed with CP before date of first ARM compared with 45 (40.5%) without CP. Baseline characteristics of patients with and without CP can be seen in Table 1 . As demonstrated, there were no statistically significant differences in baseline clinical characteristics between those with and without CP, including gender, previous childbirth, tobacco use, reason for IPAA, and age at IPAA completion or age at ARM. UC was the most common diagnosis leading to IPAA in CP and non-CP groups (89.1% and 91.1%, respectively).
Of the 111 included patients, 83 (74.8%) met criteria for the diagnosis of N-RPFD. Patients with CP were significantly more likely to be diagnosed with N-RPFD than those without (P ¼ .012) ( Table 2 ). However, there was no statistically significant difference in anastomotic strictures (P ¼ .62), abdominal and/or pelvic abscesses (P ¼ .35), or fistulae between groups (P ¼ .35). Sixty-five (78.3%) of all patients who met criteria for N-RPFD had an abnormal BET, compared with 44 patients (53.0%) with abnormal EMG, 21 patients (25.3%) with abnormal magnetic resonance or barium defecography, and 17 patients (20.5%) with 2 abnormal values on ARM (Table 3) . Of those diagnosed with N-RPFD, 60.2% met criteria based on 2 abnormal tests, with only 33 patients (39.8%) meeting diagnostic criteria based on a single abnormal test. Of those diagnosed with a single test, 22 (66.7%) were by abnormal BET. Of those remaining, 5 (15.2%) were diagnosed by anal sphincter EMG and 3 (9.1%) each by defecography and ARM. There was no significant difference in the frequency of abnormal tests between those with CP and those without. Seventy-nine patients completed ARM after IPAA. Three patients were unsuccessful in completing ARM because of discomfort/intolerance due to pain. Table 4 compares the median ARM values of those with and without N-RPFD in all patients who successfully underwent ARM. Notably, there was a statistically significant higher mean anal resting pressure in the N-RPFD group (P ¼ .019) and a trend toward more negative pouch-anal pressure gradient, although this did not reach statistical significance (P ¼ .063).
In total, 38 patients diagnosed with N-RPFD participated in biofeedback therapy (33 at Mayo Clinic and 5 at outside facilities). Of the 33 who started biofeedback at Mayo Clinic, 22 completed the 2-week course, whereas 11 were unsuccessful in doing so (7 stopped early because of pain with therapy, 3 because of time constraints, and 1 because of lack of improvement). The 22 patients were referred by a total of 17 different providers. As demonstrated in Table 5 , of those who completed biofeedback at Mayo Clinic, 22.7% experienced significant symptomatic improvement as per subjective global assessment, with 68.2% experiencing mild-moderate improvement, and 9.1% with no improvement. Twelve of the 14 patients with CP showed some level of symptomatic improvement compared with all 8 patients without CP. However, the mean Global Rating of Change scale rating at completion of biofeedback was similar between those with and without CP (þ4.8 and þ4.3, respectively), corresponding to moderate symptomatic improvement.
Of the 14 patients with CP who completed biofeedback therapy at Mayo Clinic, 5 were lost to follow-up. The remaining 9 had a mean follow-up duration of 2.8 years from the start of biofeedback. Of those 9 patients, 3 (33.3%) had resolution of CP (based on endoscopic and symptom resolution) with no further episodes of pouchitis, 1 (11.1%) had endoscopic resolution of CP with a subsequent episode of acute pouchitis that responded to a short course of antibiotics, and 5 (55.6%) had persistent CP.
Discussion N-RPFD is caused by an inability to coordinate rectoanal, abdominal, and pelvic floor muscles, 25 leading to paradoxical anal contraction and/or impaired relaxation during defecation. This is thought to be driven by maladaptive learning of sphincter contraction in response to an undesirable stimulus (ie, fear of fecal incontinence in patients with UC). 19, 21 Defecatory disorders, including N-RPFD, are common among the general population, especially those with constipation. 26 Our study suggests that defecatory disorders are also common among patients having undergone IPAA, a finding that is supported by Khanna et al 27 in their 2013 study of manometry in IPAA patients with dyschezia. The 111 patients in our study represent 9.0% of the 1233 patients who underwent IPAA at our institution during the 15-year study period. This is likely an underestimate of the actual number of patients post-IPAA that develop a defecatory disorder, because many people may not seek medical care or may present to local health providers for evaluation. Disordered defecation is an important consideration in this patient population and warrants further evaluation to determine the cause, whether due to a mechanical obstruction (ie, anastomotic stricture) or pouch dysfunction (ie, reduced pouch contractility, paradoxical anal contraction, and/or inadequate anal relaxation during defecation), to direct treatment. Among post-IPAA patients who present with symptoms suggestive of an evacuation disorder, N-RPFD seems to be quite common, because 74.8% of all patients in our study cohort met diagnostic criteria for N-RPFD. Similar to patients with an intact colon, N-RPFD may develop in patients post-IPAA as a maladaptive response to the voluntary holding of stool. 20 We theorize that this maladaptive behavior begins before colectomy in patients with UC because of increased bowel movement frequency and fear of incontinence. Post-IPAA, frequent defecation remains an issue for many patients. As demonstrated in a meta-analysis of more than 5000 patients in 26 observational studies, the mean defecation frequency after IPAA was 5.9 per 24 hours. 28 Thus, paradoxical anal contraction and/or failure to relax may develop as a consequence of the voluntary holding of stool and recurrent recruitment of pelvic floor muscles in the setting of frequent defecation both before and after IPAA.
Moreover, N-RPFD is significantly more common in patients with CP compared with those without (P ¼ .012). The reason for this is not entirely clear, but we hypothesize that fecal stasis may play a significant role. Fecal stasis caused by impaired evacuation of pouch contents is thought to promote the alteration of commensal intestinal bacteria and bacterial overload, leading to subsequent pouch inflammation. 15, 18 The role of fecal stasis in the development of pouch inflammation is supported by animal models in which inflammatory markers were significantly elevated in the pouches of rats with radiographic evidence of fecal stasis compared with those without. 29, 30 Further investigation into the role of fecal stasis in the development of pouchitis is needed. We argue, however, that any patient post-IPAA with CP and with symptoms suggestive of a pouch evacuation disorder be evaluated for N-RPFD.
Establishing the diagnosis of N-RPFD in patients is important, because this is a potentially treatable disorder. Biofeedback therapy aimed at improving the relaxation of anal and pelvic floor muscles during defecation has become the mainstay of management. 31 Multiple randomized controlled trials have demonstrated the efficacy of biofeedback therapy compared with both standard therapy (ie, diet, exercise, and/or laxatives) and sham biofeedback in patients with dyssynergic defecation. 22, 23 Although initial studies focused on short-term benefit, a prospective randomized controlled trial in 2010 demonstrated sustained symptomatic and objective measure improvement (ie, improved balloon expulsion time) at 12 months following biofeedback compared with standard therapy. 32 Our study demonstrates that biofeedback is similarly efficacious in the symptomatic improvement of patients with IPAA diagnosed with N-RPFD. In all, 22 patients completed pelvic floor retraining with symptomatic improvement experienced in 90.9%. These findings suggest that, similar to patients with an intact colon, biofeedback therapy is efficacious in patients with an IPAA who are diagnosed with N-RPFD. However, further research is needed to confirm this and also to assess the effect of biofeedback on pouch inflammation in patients with CP. Preferably, this would include a prospective study with longer study duration (at least 1 year follow-up post biofeedback) with serial objective measures (ie, ARM, BET, anal EMG, and pouchoscopy) before and after therapy at designated intervals.
This study has several limitations, one of which is the uncertainty regarding the diagnostic criteria for N-RPFD, specifically in patients with IPAA. In fact, there are presently no standard criteria for the diagnosis of N-RPFD. N-RPFD, or dyssynergic defecation, is typically defined by the presence of symptoms consistent with a defecatory disorder plus objective data demonstrating impaired defecation and a dyssynergic defecatory pattern. This typically involves the use of ARM and BET in addition to defecography and/or EMG if initial testing is inconclusive. 31 However, normal values vary considerably and there is limited agreement among the various diagnostic tests. 31 Furthermore, normal values are derived from healthy, asymptomatic individuals with an intact colon. There are no normative data to facilitate the use of these diagnostic tests in patients with an IPAA. This issue is highlighted in Table 4 , which shows the median ARM values in our study cohort. Although the N-RPFD group has a significantly higher resting anal pressure, consistent with what would be expected in N-RPFD, these values fall within the age-and genderbased normal reference ranges derived from healthy control subjects with an intact colon. Further studies are required to establish normative data for the diagnosis of N-RPFD in patients with an IPAA and also to validate these diagnostic methods in this subset of patients.
A second limitation is the fact that this is a retrospective study, which limits the data available for abstraction. We had to rely on the accuracy of available data in the electronic medical record to determine the diagnosis of CP and N-RPFD in the study cohort. Additionally, as a retrospective study, we are unable to definitively prove that N-RPFD leads to the development of CP. In fact, some may argue that CP may develop first and contribute to the subsequent development of N-RPFD. This needs to be evaluated further, preferably with a prospective study. Third, our study had a relatively small sample size, although sufficient for detection of clinically and statistically significant findings. Lastly, this is a single center study, which limits the generalizability of our findings, especially to community or nonreferral centers. Ultimately, a larger, prospective, multicenter study could help to overcome many of the these limitations.
In conclusion, patients with an IPAA who present with symptoms suggestive of a pouch evacuation disorder warrant further evaluation, as N-RPFD appears to be quite common in this patient population. This is especially true in patients with CP, although additional studies are needed to further evaluate the relationship between N-RPFD and CP. Similar to patients with an intact colon, biofeedback seems to be an effective therapy for N-RPFD in patients with an IPAA. Further investigation is needed to better define N-RPFD diagnostic criteria and to establish normative data for diagnostic testing in patients with an IPAA.
